組織特異的カドヘリンCDH17は、CDX2よりも高い感度を持つ胃腸腺癌の有用なマーカーです

カドヘリン17（CDH17）は、腸上皮で発現した細胞接着分子であり、CDX2によって転写的に調節されています。免疫組織化学腸マーカーとしてのCDH17の有用性を、胃腸癌および骨膜外癌および非腫瘍組織におけるCDX2の有用性と比較しました。非腫瘍性腸および膵管上皮はCDH17陽性でした。ほとんどの食道（79％）、胃（86％）、および結腸（99％）腺癌はCDH17陽性/CDX2陽性でしたが、結腸の1％、食道の18％、ガストリック腺癌腫の10％はCDH17-感染性でした。/CDX2陰性。まれな結腸、食道、および胃腺癌は、CDH17陽性/CDX2陰性（それぞれ1％、3％、および4％）であり、CDH17陰性/CDX2陽性はありませんでした。びまん性CDH17は、すべての転移性結腸癌でも観察され、その20％は局所的にCDX2陽性のみでした。腸の低悪性度神経内分泌腫瘍の、74％がCDX2とCDH17を共発現しました。CDH17は、膵臓の12％および気管支内性内分泌腫瘍の24％でも陽性であり、それらはすべてCDX2陰性でした。膵臓腺癌および胆管癌は、CDX2陽性よりもCDH17陽性でした（50％対27％、53％対27％）。1つの（2％）肝細胞癌はCDH17陽性/CDX2陰性でした。非小細胞肺癌の9％と子宮内膜がんの7％はCDH17陽性でしたが、肺の3％、子宮内膜の5％、卵巣の3％、乳がんの2％はCDX2陽性でした。したがって、胃腸腺癌を検出すると、CDH17はCDX2よりもわずかに敏感です。

Cadherin 17 (CDH17) is a cell adhesion molecule expressed in intestinal epithelium and transcriptionally regulated by CDX2. We compared the usefulness of CDH17 as an immunohistochemical intestinal marker to that of CDX2 in gastrointestinal and extragastrointestinal carcinomas and nonneoplastic tissues. Nonneoplastic intestinal and pancreatic duct epithelia were CDH17-positive. Most esophageal (79%), gastric (86%), and colonic (99%) adenocarcinomas were CDH17-positive/CDX2-positive, whereas 1% of colonic, 18% of esophageal, and 10% of gastric adenocarcinomas were CDH17-negative/CDX2-negative. Rare colonic, esophageal, and gastric adenocarcinomas were CDH17-positive/CDX2-negative (1%, 3%, and 4%, respectively), and none were CDH17-negative/CDX2-positive. Diffuse CDH17 was also observed in all metastatic colon carcinomas, 20% of which were only focally CDX2-positive. Of intestinal low-grade neuroendocrine tumors, 74% coexpressed CDX2 and CDH17. CDH17 was also positive in 12% of pancreatic and 24% of bronchial neuroendocrine tumors, all of which were CDX2-negative. Pancreatic adenocarcinomas and cholangiocarcinomas were more frequently CDH17-positive than CDX2-positive (50% vs 27%, 53% vs 27%). One (2%) hepatocellular carcinoma was CDH17-positive/CDX2-negative. Nine percent of non-small cell lung cancers and 7% of endometrial carcinomas were CDH17-positive, whereas 3% of lung, 5% of endometrial, 3% of ovarian, and 2% of breast carcinomas were CDX2-positive. Thus, CDH17 is slightly more sensitive than CDX2 when detecting gastrointestinal adenocarcinomas.